Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

BACKGROUND: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Louis, Edouard, Resche-Rigon, Matthieu, Laharie, David, Satsangi, Jack, Ding, Nik, Siegmund, Britta, D'Haens, Geert, Picon, Laurence, Bossuyt, Peter, Vuitton, Lucine, Irving, Peter, Viennot, Stephanie, Lamb, Christopher A, Pollok, Richard, Baert, Filip, Nachury, Maria, Fumery, Mathurin, Gilletta, Cyrielle, Almer, Sven, Ben-Horin, Shomron, Bouhnik, Yoram, Colombel, Jean-Frederic, Hertervig, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908559/
https://www.ncbi.nlm.nih.gov/pubmed/36640794
http://dx.doi.org/10.1016/S2468-1253(22)00385-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908559/
https://www.ncbi.nlm.nih.gov/pubmed/36640794
http://dx.doi.org/10.1016/S2468-1253(22)00385-5

Ejemplares similares